Skip to main content
. 2021 Mar 9;4(3):e210980. doi: 10.1001/jamanetworkopen.2021.0980

Figure 2. Multivariable Analysis of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors (ICIs) .

Figure 2.

Single-agent ICI indicates programmed death cell ligand 1 or cytotoxic T-lymphocyte antigen 4 inhibition, while dual-agent ICI indicates concurrent ipilimumab and nivolumab. ECOG indicates Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; M1a, patients with nonregional lymph nodes and/or skin or soft tissue lesions; M1b, patients with lung metastases; M1c, patients with all other visceral sites of disease (including liver involvement); M1d, patients with central nervous system metastases; PFS, progression-free survival; WRL, within reference limits (ie, ≤240 U/L [to convert to microkatals per liter, multiply by 0.0167]); WT, wild type.